Skip to main content
  • Home
  •  Challenges in ATTR Amyloidosis: An Expert Debate

Challenges in ATTR Amyloidosis: An Expert Debate

Topic:
  • Amyloidosis

Available Credit:

  • 1.00 EBAC

Course Published On:

Course Expiry Date:

Challenges in ATTR Amyloidosis: An Expert Debate
No ratings

Overview

Radcliffe Medical Education bring together a globally-renowed faculty, including Prof Thibaud Damy (Creteil, FR) as he chairs a panel of distinguished experts, Dr Esther González López (Madrid, SP), Dr João R. Agostinho (Lisbon, PT) and Dr Ahmad Masri (Portland, USA) in a interactive symposium centred around three distinctive challenges facing physicians when diagnosing and treating ATTR-CM patients. 

 

During this session, the panel discuss key challenges in ATTR Amyloidosis including identifying ATTR in regular cardiac clinic, managing patients with a mixed phenotype and disease modifying treating for ATTR-CM.  

Disclosure

In compliance with EBAC guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

Terms & Conditions

Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.

 

The session, ‘Individualising Antithrombotic Strategies for Established Coronary Artery Disease’ is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credits.

 

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

 

Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionalsand the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.

Support Statement

This Satellite Symposium was supported by an unrestricted educational grant from AstraZeneca who has no involvement in the content.

Instruction to Participants

There is no fee for taking part in this online learning activity.

 

Activities are designed to be completed within 90 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.

 

To complete the course and claim certification participants must:

  • Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
  • Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.

Target Audience

  • Heart Failure Specialists
  • Cardiac Amyloidosis Specialists
  • Echocardiologists

Learning Objectives

  • Comprehend the unique challenges posed to cardiologists who encounter patients with ATTR amyloidosis
  • Initiate first steps in diagnosis of suspect individuals in accordance to latest guidance
  • Have enhanced awareness of the disease trajectory of patients with a mixed ATTR phenotype
  • Recall the limitations of existing therapies for ATTR-CM
  • List the advantages of emerging classes of agents being evaluated in ATTR-CM
Register now Log in

Module

Title

Duration

Speakers

Session 1 Welcome and Introduction 2m 32s Thibaud Damy
Session 2 Identifying ATTR in a Regular Cardiac Clinic 19m 8s Esther González López
Session 3 Managing Patients with a Mixed Phenotype 16m 41s João R Agostinho
Session 4 Disease Modifying Treatment for ATTR-CM 16m 49s Ahmad Masri
Session 5 Closing Remarks 39s Thibaud Damy
Session 1.

Welcome and Introduction

Duration: 2m 32s

Speakers: Thibaud Damy

Session 2.

Identifying ATTR in a Regular Cardiac Clinic

Duration: 19m 8s

Speakers: Esther González López

Session 3.

Managing Patients with a Mixed Phenotype

Duration: 16m 41s

Speakers: João R Agostinho

Session 4.

Disease Modifying Treatment for ATTR-CM

Duration: 16m 49s

Speakers: Ahmad Masri

Session 5.

Closing Remarks

Duration: 39s

Speakers: Thibaud Damy

Course Director

Thibaud Damy

Henri Mondor Hospital, Créteil, France

Prof Thibaud Damy is a cardiologist focusing on heart failure and cardiac amyloidosis. He works at Hospital Henri Mondor and Paris East Creteil University (UPEC), and is part of INSERM U955.

View full profile

Speaker

João R Agostinho

Hospital Universita­rio de Santa Maria, Lisbon, PT

Dr João R. Agostinho is a prominent cardiologist and researcher based in Lisbon, Portugal.

View full profile

Ahmad Masri

Oregon Health & Science University Medical Group, Portland, USA

Dr Ahmad Masri M.D., M.S. trained in Internal Medicine at the Cleveland Clinic.

He specialises in caring for patients with conditions that result in abnormally thickened hearts, such as hypertrophic cardiomyopathy, amyloidosis and Fabry’s disease.

View full profile

Esther González López

Hospital Puerta de Hierro Majadahonda, Madrid, SP

Dr. Gonzalez-Lopez trained in Cardiology at Hospital Puerta de Hierro Majadahonda (HUPHM) in Madrid, where she completed her doctoral thesis on imaging techniques in transthyretin cardiac amyloidosis.

View full profile
1.00 EBAC

Challenges in ATTR Amyloidosis: An Expert Debate's programme has been accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 CME point, equating to 1 hour of learning. Physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™.

Related Courses

Cardiac Amyloidosis: Emerging Diagnostic and Treatment Approaches
  • 1.00 EBAC

Learning objectives

  • Understand the nature of amyloidosis and its effects on various organs, particularly the heart
  • Distinguish between light-chain (AL) amyloidosis, wild type TTR amyloidosis and hereditary TTR amyloidosis in terms of their clinical manifestations and their different treatments
  • Recognise the novel challenges of managing heart failure in cardiac amyloidosis, including both medical management and the role of devices
  • Understand the critically important interaction between haematologists and cardiologists in the therapy of AL amyloidosis
  • Develop an understanding of novel therapies currently in clinical trials of TTR and AL amyloidosis
  • Identify their own roles and responsibilities in the management TTR and AL amyloidosis as part of a multidisciplinary team
See more